415 related articles for article (PubMed ID: 16824147)
1. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function.
Qazi YA; Forrest A; Tornatore K; Venuto RC
Clin Transplant; 2006; 20(3):313-7. PubMed ID: 16824147
[TBL] [Abstract][Full Text] [Related]
2. Neoral-to-Gengraf conversion in renal transplant recipients.
Carnahan W; Cooper TY
Transplant Proc; 2003 Jun; 35(4):1308-13. PubMed ID: 12826145
[TBL] [Abstract][Full Text] [Related]
3. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring.
Sharma A; Shekhar C; Heer M; Minz M
Transplant Proc; 2006 Sep; 38(7):2051-3. PubMed ID: 16979996
[TBL] [Abstract][Full Text] [Related]
4. Safe conversion to cicloral, a generic cylosporine, in both stable and de novo renal transplant recipients.
Kahn D; Muller E; Pascoe M
Saudi J Kidney Dis Transpl; 2010 May; 21(3):426-32. PubMed ID: 20427863
[TBL] [Abstract][Full Text] [Related]
5. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation.
Roza A; Tomlanovich S; Merion R; Pollak R; Wright F; Rajagopalan P; Pruett T; Scandling J; Ryan J; Awni W; Schweitzer S; Greco R; Lam W; Nabulsi A; Hoffman R
Transplantation; 2002 Oct; 74(7):1013-7. PubMed ID: 12394847
[TBL] [Abstract][Full Text] [Related]
6. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
[TBL] [Abstract][Full Text] [Related]
7. Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year.
Neumayer HH; Budde K; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
Clin Nephrol; 1996 May; 45(5):326-31. PubMed ID: 8738665
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, efficacy, and safety of Iminoral compared with Neoral in healthy volunteers and renal transplant recipients.
Sayyah M; Argani H; Pourmand GR; Amini H; Ahmadiani A
Transplant Proc; 2007 May; 39(4):1214-8. PubMed ID: 17524936
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of generic cyclosporine arpimune in Filipino low-risk primary kidney transplant recipients.
Pamugas GE; Danguilan RA; Lamban AB; Mangati VB; Ona ET
Transplant Proc; 2012 Jan; 44(1):101-8. PubMed ID: 22310590
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
White M; Pelletier GB; Tan A; Jesina C; Carrier M
J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic equivalence and mg:mg switch ability of a generic cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients maintained on Sandimmun Neoral.
Al Wakeel JS; Shaheen FA; Mathew MC; Abouzeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
Transplant Proc; 2008 Sep; 40(7):2252-7. PubMed ID: 18790206
[TBL] [Abstract][Full Text] [Related]
12. Generic cyclosporine formulations: more open questions than answers.
Cattaneo D; Perico N; Remuzzi G
Transpl Int; 2005 Apr; 18(4):371-8. PubMed ID: 15773953
[TBL] [Abstract][Full Text] [Related]
13. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
Carstens J
Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of cyclosporine: 20 years of progress.
Kahan BD
Transplant Proc; 2004 Mar; 36(2 Suppl):378S-391S. PubMed ID: 15041372
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of equoral versus neoral in stable renal transplant patients: a multinational multicenter study.
Masri MA; Haberal M; Rizvi A; Stephan A; Bilgin N; Naqvi A; Barbari A; Kamel G; Zafar N; Emiroğlu R; Colak T; Manzoor K; Matha V; Kamarad V; Rizk S; Itany AR; Shehedeh I
Transplant Proc; 2004; 36(1):80-3. PubMed ID: 15013306
[TBL] [Abstract][Full Text] [Related]
16. Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year.
Neumayer HH; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Budde K; Waiser J; Luft FC
Nephrol Dial Transplant; 1996 Jan; 11(1):165-72. PubMed ID: 8649628
[TBL] [Abstract][Full Text] [Related]
17. [Conversion from +Sandimmune to Neoral in kidney transplant recipients treated with cyclosporine and ketoconazole].
Videla C; Vega J; Borja H; Gatica A; Clavero R; Aldunate T
Rev Med Chil; 1997 Apr; 125(4):438-45. PubMed ID: 9460285
[TBL] [Abstract][Full Text] [Related]
18. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients.
Kobashigawa JA; Patel J; Furukawa H; Moriguchi JD; Yeatman L; Takemoto S; Marquez A; Shaw J; Oeser BT; Subherwal S; Wu GW; Kawano J; Laks H
J Heart Lung Transplant; 2006 Apr; 25(4):434-9. PubMed ID: 16563974
[TBL] [Abstract][Full Text] [Related]
19. A bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients.
Leet A; Richardson M; Senior JA; Funston R; Skiba M; Bailey M; Krum H
J Heart Lung Transplant; 2009 Sep; 28(9):894-8. PubMed ID: 19716041
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience transferring kidney transplant patients from Sandimmun to Sandimmun Neoral--results after 3 months.
Neumayer HH; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J
Clin Nephrol; 1995 Jan; 43 Suppl 1():S27-32. PubMed ID: 7781202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
